Clinical trials: Node-positive Breast Cancer
Triple Negative Breast Cancer, HER2-negative Breast Cancer
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast…
- Trial name
- DecipHER (NCT05504707)
- Testing
- HER2 - primed Dendritic cells, HER3 - primed Dendritic cells
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Neoplasm Metastasis
Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
The purpose of this study is to evaluate the safety of administering a single dose of trastuzumab into the artery for the treatment of brain metastasis(es) from HER2/neu positive breast cancer.
- Trial name
- NCT02571530
- Testing
- Intra-arterial Cerebral Infusion of Trastuzumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Northwell Health
Breast Neoplasms
Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.
- Trial name
- NCT00431067
- Testing
- BIBW 2992
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
This research study is studying a drug as a possible treatment for ER-positive Breast Cancer The drug involved in this study is: -Ribociclib
- Trial name
- LEADER (NCT03285412)
- Testing
- Ribociclib, Endocrine therapy
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer, Neoadjuvant Therapy
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer
Today, the majority of clinically node positive (cN+) breast cancer patients is treated with neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients are areas of controversy.
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Lymph Node Metastases
- Trial name
- MINIMAX (NCT04486495)
- Where
- 35 sites in Netherlands
- Volunteers
- 549 people
- Sponsor
- Maastricht University Medical Center
Male Breast Cancer, Recurrent Breast Cancer
Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors
Phase I trial to study the effectiveness of interleukin-12, paclitaxel, and trastuzumab in treating patients who have solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastric Cancer
- Trial name
- NCT00028535
- Testing
- trastuzumab, paclitaxel, recombinant interleukin-12
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Cardiac Toxicity
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
RATIONALE: Lisinopril or Coreg CR®, may help reduce side effects caused by trastuzumab. It is not yet known whether lisinopril or Coreg CR® are more effective than a placebo in reducing side effects caused by trastuzumab.
- Trial name
- NCT01009918
- Testing
- Coreg CR®, lisinopril
- Where
- 174 sites in United States
- Volunteers
- 468 people
- Sponsor
- University of South Florida
Breast Cancer
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
- Trial name
- NCT04850625
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Fudan University
Breast Cancer
12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)
This phase II trial aims to study the efficacy and safety of 12 weeks adjuvant docetaxel plus trastuzumab in patients with tumors ≤1cm, node-negative, HER2-positive breast cancer.
- Trial name
- SOBER (NCT03367676)
- Testing
- Trastuzumab, Docetaxel
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Ruijin Hospital
Breast Cancer
High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy
RATIONALE: High doses of esterified estrogens may stop the growth of breast cancer cells that no longer respond to hormone therapy.
- Trial name
- NCT00131924
- Testing
- esterified estrogens
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Northwestern University
Metastatic Breast Cancer
Τreatment Standards and Outcomes of Patients With ER/PR Positive, HER2-negative Metastatic Breast Cancer
To capture the treatment patterns and clinical characteristics of patients with ER/PR positive, HER2-negative MBC in Greece
- Trial name
- MBC (NCT04247035)
- Where
- Greece
- Volunteers
- 300 people
- Sponsor
- Hellenic Society of Medical Oncology
Hormone Receptor-Positive Breast, Gynecologic
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Background: Some types of cancer cells that have hormone receptors on their surfaces need the hormone estrogen to grow. The drug tamoxifen blocks estrogen from binding to the tumor cells, which helps to slow or stop the growth of…
- Conditions
- Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
- Trial name
- NCT01273168
- Testing
- Z-Endoxifen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Breast Cancer
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
- Trial name
- NCT06533059
- Testing
- ALTA2618
- Where
- 31 sites in United States, Australia and 6 more
- Volunteers
- 110 people
- Sponsor
- Alterome Therapeutics, Inc.
Cancer
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone
This was a randomized, open-label, multi-center Phase III study evaluating the efficacy and safety of lapatinib in combination with trastuzumab versus trastuzumab alone as continued HER2 suppression therapy in women with…
- Trial name
- NCT00968968
- Testing
- Lapatinib, Trastuzumab
- Where
- 116 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain.
- Trial name
- NCT01494662
- Testing
- HKI-272, Surgical Resection, Capecitabine
- Where
- 18 sites in United States
- Volunteers
- 140 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors.
- Trial name
- NCT07287917
- Testing
- AMXT 1501 Dicaprate, DFMO, Fulvestrant
- Where
- 20 sites in United States
- Volunteers
- 92 people
- Sponsor
- Aminex Therapeutics, Inc.
Breast Neoplasms
GETNA2 Neoadj. TAX+Femara vs Femara in g I/II Breast Cancer
Primarily to evaluate the rates of clinical and radiological response in the 2 groups. Secondarily rate of histological response.
- Trial name
- NCT00617968
- Testing
- DOCETAXEL
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Sanofi
Breast Cancer
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
It suggests in the Guideline that the postmenopausal women with breast cancer who have taken selective estrogen receptor modulators (SERMs) therapy for 2-3 years could benefit from changing endocrine therapy to aromatase…
- Trial name
- NCT02097459
- Testing
- Anastrozole, Tamoxifen, Toremifene
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking Union Medical College Hospital
Breast Cancer Stage IV
Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer
This study recruits patients with metastatic breast cancer who have progressed on their current regimen of dual anti-HER2 therapy.
- Trial name
- SIMPHONY (NCT03324425)
- Testing
- Simvastatin 80mg
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Baylor Breast Care Center
Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Patients with advanced HER2+ breast cancer on maintenance trastuzumab/pertuzumab or T-DM1 with 1st or 2nd intracranial disease event (brain metastases) and stable extracranial disease will be enrolled.
- Conditions
- Brain Metastases, Human Epidermal Growth Factor 2 Positive Carcinoma of Breast, Advanced Breast Cancer
- Trial name
- BRIDGET (NCT05323955)
- Testing
- Trastuzumab, Trastuzumab Emtansine (T-DM1), Pertuzumab
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carey Anders, M.D.